🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 1 día
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 21/05/2010 | 35,34 | 35,64 | 34,06 | 34,12 | -4,10% | 4,47% | 5.269.000 |
| 20/05/2010 | 36,76 | 36,88 | 35,48 | 35,58 | -4,92% | 3,81% | 2.155.600 |
| 19/05/2010 | 37,11 | 37,72 | 36,78 | 37,42 | +0,89% | 2,53% | 1.772.200 |
| 18/05/2010 | 37,76 | 38,08 | 37,07 | 37,09 | -1,25% | 2,67% | 1.002.100 |
| 17/05/2010 | 38,06 | 38,73 | 36,69 | 37,56 | +0,27% | 5,36% | 1.437.100 |
| 14/05/2010 | 38,39 | 38,56 | 37,14 | 37,46 | -2,65% | 3,70% | 1.636.600 |
| 13/05/2010 | 38,24 | 38,92 | 38,10 | 38,48 | -0,75% | 2,14% | 1.501.500 |
| 12/05/2010 | 38,06 | 38,94 | 37,78 | 38,77 | +1,73% | 3,05% | 1.604.800 |
| 11/05/2010 | 37,22 | 38,46 | 37,02 | 38,11 | +1,49% | 3,87% | 1.777.100 |
| 10/05/2010 | 37,50 | 37,62 | 36,97 | 37,55 | +4,60% | 1,73% | 2.379.100 |
| 07/05/2010 | 36,83 | 37,09 | 34,93 | 35,90 | -2,71% | 5,86% | 3.380.600 |
| 06/05/2010 | 37,68 | 37,68 | 34,26 | 36,90 | -1,73% | 9,08% | 4.164.900 |
| 05/05/2010 | 38,20 | 38,68 | 37,00 | 37,55 | -2,39% | 4,40% | 2.933.300 |
| 04/05/2010 | 38,49 | 38,96 | 37,95 | 38,47 | -1,28% | 2,62% | 1.964.200 |
| 03/05/2010 | 38,77 | 39,29 | 38,38 | 38,97 | +0,52% | 2,35% | 1.208.400 |
| 30/04/2010 | 39,06 | 39,83 | 38,69 | 38,77 | -1,97% | 2,92% | 1.343.800 |
| 29/04/2010 | 38,60 | 39,64 | 38,42 | 39,55 | +2,62% | 3,16% | 1.247.600 |
| 28/04/2010 | 38,78 | 38,99 | 38,36 | 38,54 | -0,34% | 1,62% | 1.139.900 |
| 27/04/2010 | 38,50 | 39,30 | 38,50 | 38,67 | +0,44% | 2,08% | 2.351.900 |
| 26/04/2010 | 38,63 | 38,99 | 38,38 | 38,50 | -0,65% | 1,58% | 932.000 |
| 23/04/2010 | 38,42 | 38,81 | 37,87 | 38,75 | +1,73% | 2,45% | 1.435.800 |
| 22/04/2010 | 39,06 | 39,06 | 37,98 | 38,09 | -3,20% | 2,76% | 2.325.600 |
| 21/04/2010 | 40,37 | 40,47 | 39,10 | 39,35 | -2,84% | 3,39% | 1.920.000 |
| 20/04/2010 | 40,23 | 40,55 | 39,71 | 40,50 | +1,15% | 2,09% | 1.603.200 |
| 19/04/2010 | 40,00 | 40,26 | 39,66 | 40,04 | +0,13% | 1,50% | 2.245.500 |
| 16/04/2010 | 39,62 | 40,12 | 38,92 | 39,99 | +0,83% | 3,03% | 2.677.000 |
| 15/04/2010 | 39,76 | 40,22 | 39,23 | 39,66 | -0,83% | 2,49% | 1.627.100 |
| 14/04/2010 | 40,09 | 40,21 | 39,51 | 39,99 | -0,05% | 1,75% | 1.292.400 |
| 13/04/2010 | 39,24 | 40,17 | 38,94 | 40,01 | +1,91% | 3,13% | 2.185.200 |
| 12/04/2010 | 38,77 | 39,75 | 38,22 | 39,26 | -1,06% | 3,95% | 2.763.600 |